Human interleukin-2

SYNCAR-001 + STK-009, developed for B-cell lymphomas and other conditions, uses T cells modified to target CD19. Synthekine, focusing on cytokine therapies, is behind its development. GlobalData provides analytics on drug approval likelihood, leveraging historical data and machine learning.

Imugene dosed the first Australian subject in a Phase Ib trial for azer-cel, targeting relapsed or refractory DLBCL. This off-the-shelf CAR T-cell therapy aims to reduce treatment times and improve access, with promising outcomes reported from US trial sites.

Imugene Ltd initiated a Phase 1b trial at Royal Prince Alfred Hospital, Sydney, dosing the first Australian patient with azer-cel for relapsed or refractory DLBCL. Azer-cel, an off-the-shelf CAR T-cell therapy, aims to reduce treatment timelines and cost, showing promise in US trials with complete responses in some patients.

Mural Oncology focuses on engineered cytokine therapies for cancer, with lead candidate Nemvaleukin alfa. Key trials ARTISTRY-7 and ARTISTRY-6 are underway, with data readouts expected in 2025. The company plans a Biologics License Application submission based on ARTISTRY-7 results. Mural ended September 2024 with $175.5 million in cash.

The article references multiple studies on inflammatory bowel disease (IBD), focusing on its global burden, increasing incidence, and the role of innate lymphoid cells (ILCs) in intestinal homeostasis and inflammation. It highlights the importance of microbiota in regulating ILC function and the potential of targeting ILCs for IBD therapy.

SYNCAR-001 + STK-009, developed by Synthekine, targets B-cell lymphomas and autoimmune diseases using CAR-T cells. Synthekine focuses on cytokine therapies for cancer and autoimmune disorders, with headquarters in Menlo Park, California.

Indapta Therapeutics collaborates with Sanofi to evaluate allogeneic g-NK cell therapy, IDP-023, combined with Sarclisa in relapsed/refractory multiple myeloma patients. The phase 1 study will explore up to three dose levels of IDP-023 in combination with Sarclisa, with Indapta sponsoring the trial and Sanofi supplying the drug.

TILT Biotherapeutics presents data at ESMO-IO 2024 on personalized treatment strategies with TILT-123, an oncolytic virus, showing improved clinical trial outcomes. The study identifies immunological markers linked to better patient responses and supports the formation of immunological memory. TILT plans to advance TILT-123 into international Phase II trials for ovarian cancer, with expected Phase Ib results by H2 2025.

Aulos Bioscience announced the first patients dosed in a Phase I/II trial investigating avelumab, in combination with imneskibart and low-dose, subcutaneous aldesleukin, for non-small cell lung cancer. The trial follows a collaboration and supply agreement with Merck, evaluating the combination therapy for second-line treatment. Pre-clinical results showed strong anti-cancer activity, including complete tumour eradication.